Since the initial hallmark paper demonstrating the ability of rapamycin to downregulate tumour VEGF levels29, the ability of mTOR inhibitors to elicit antiangiogenic effects by downregulation of VEGF, made them key candidates for the investigation of new combined chemotherapy regimens. The gene discussed is MTOR; the disease is neoplasm.